204 related articles for article (PubMed ID: 12495304)
1. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity.
Coca S; Perazella MA
Am J Med Sci; 2002 Dec; 324(6):342-4. PubMed ID: 12495304
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir-related nephrotoxicity in HIV-infected patients.
Barrios A; García-Benayas T; González-Lahoz J; Soriano V
AIDS; 2004 Apr; 18(6):960-3. PubMed ID: 15060449
[No Abstract] [Full Text] [Related]
3. Tenofovir disoproxil fumarate.
Antoniou T
Drugs; 2003; 63(15):1609-10. PubMed ID: 12887266
[No Abstract] [Full Text] [Related]
4. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
Fung HB; Stone EA; Piacenti FJ
Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
[TBL] [Abstract][Full Text] [Related]
5. Renal lesions in HIV-1-positive patient treated with tenofovir.
Créput C; Gonzalez-Canali G; Hill G; Piketty C; Kazatchkine M; Nochy D
AIDS; 2003 Apr; 17(6):935-7. PubMed ID: 12660548
[No Abstract] [Full Text] [Related]
6. Tenofovir disoproxil fumarate.
Kumar A
Drugs; 2003; 63(15):1609-10. PubMed ID: 12887267
[No Abstract] [Full Text] [Related]
7. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.
Squires K; Pozniak AL; Pierone G; Steinhart CR; Berger D; Bellos NC; Becker SL; Wulfsohn M; Miller MD; Toole JJ; Coakley DF; Cheng A;
Ann Intern Med; 2003 Sep; 139(5 Pt 1):313-20. PubMed ID: 12965939
[TBL] [Abstract][Full Text] [Related]
8. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution.
Gaspar G; Monereo A; García-Reyne A; de Guzmán M
AIDS; 2004 Jan; 18(2):351-2. PubMed ID: 15075563
[No Abstract] [Full Text] [Related]
9. Tenofovir induced acute kidney injury in a patient with unilateral renal agenesis despite initially non-impaired renal function.
Schleenvoigt BT; Stallmach A; Pletz MW
Eur J Med Res; 2011 Dec; 16(12):564. PubMed ID: 22112365
[TBL] [Abstract][Full Text] [Related]
10. Renal safety of tenofovir in HIV treatment-experienced patients.
Izzedine H; Isnard-Bagnis C; Hulot JS; Vittecoq D; Cheng A; Jais CK; Launay-Vacher V; Deray G
AIDS; 2004 Apr; 18(7):1074-6. PubMed ID: 15096814
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir-related nephrotoxicity: case report and review of the literature.
James CW; Steinhaus MC; Szabo S; Dressier RM
Pharmacotherapy; 2004 Mar; 24(3):415-8. PubMed ID: 15040657
[TBL] [Abstract][Full Text] [Related]
12. Severe metabolic acidosis and renal failure in an HIV-1 patient receiving tenofovir.
Hansen AB; Mathiesen S; Gerstoft J
Scand J Infect Dis; 2004; 36(5):389-92. PubMed ID: 15287389
[TBL] [Abstract][Full Text] [Related]
13. Fanconi syndrome and renal failure induced by tenofovir: a first case report.
Verhelst D; Monge M; Meynard JL; Fouqueray B; Mougenot B; Girard PM; Ronco P; Rossert J
Am J Kidney Dis; 2002 Dec; 40(6):1331-3. PubMed ID: 12460055
[TBL] [Abstract][Full Text] [Related]
14. Summaries for patients. Treatment for resistant HIV-1 infection.
Ann Intern Med; 2003 Sep; 139(5 Pt 1):I22. PubMed ID: 12965954
[No Abstract] [Full Text] [Related]
15. Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity?
Saumoy M; Vidal F; Peraire J; Sauleda S; Vea AM; Viladés C; Ribera E; Richart C
AIDS; 2004 Aug; 18(12):1741-2. PubMed ID: 15280790
[No Abstract] [Full Text] [Related]
16. Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies.
Schmid S; Opravil M; Moddel M; Huber M; Pfammatter R; Keusch G; Ambuhl P; Wuthrich RP; Moch H; Varga Z
Virchows Arch; 2007 Jun; 450(6):665-70. PubMed ID: 17464512
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.
Antoniou T; Park-Wyllie LY; Tseng AL
Pharmacotherapy; 2003 Jan; 23(1):29-43. PubMed ID: 12523458
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
[TBL] [Abstract][Full Text] [Related]
19. Acute tubular necrosis in a patient receiving tenofovir.
Lee JC; Marosok RD
AIDS; 2003 Nov; 17(17):2543-4. PubMed ID: 14600530
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
Gallant JE; Staszewski S; Pozniak AL; DeJesus E; Suleiman JM; Miller MD; Coakley DF; Lu B; Toole JJ; Cheng AK;
JAMA; 2004 Jul; 292(2):191-201. PubMed ID: 15249568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
